Last reviewed · How we verify
PF-07104091 (pf-07104091)
PF-07104091, marketed by Pfizer Inc., holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its current marketed status, providing a steady revenue stream for Pfizer. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | pf-07104091 |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Understand How the Body Processes [14C]PF-07104091 in Healthy Participants (PHASE1)
- PF-07104091 as a Single Agent and in Combination Therapy (PHASE2)
- A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors (PHASE1, PHASE2)
- A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07104091 CI brief — competitive landscape report
- PF-07104091 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI